Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-Induced Cardiomyopathy in the Elderly

  • Elderly + Heart Disease (J Wei, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

The older population is preferentially afflicted by cancer and is vulnerable to chemotherapy-related side effects including cardiotoxicity. Unfortunately, this high-risk group is underrepresented in clinical trials and as such there is little guidance for risk assessment and management. In this review, we focus on the commonly used chemotherapeutic agents and their deleterious cardiovascular effects, particularly in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41.

    Article  PubMed  Google Scholar 

  2. Kendal WS. Dying with cancer. Cancer. 2008;112(6):1354–62.

    Article  PubMed  Google Scholar 

  3. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900–5.

    Article  CAS  PubMed  Google Scholar 

  4. Cardinale D et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. This study evaluated the effect of enalapril and carvedilol on left ventricular systolic function and cardiac outcomes in patients who developed anthracycline induced cardiomyopathy.

    Article  CAS  PubMed  Google Scholar 

  5. Du XL et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115(22):5296–308.

    Article  PubMed  Google Scholar 

  6. Pinder MC et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808–15.

    Article  CAS  PubMed  Google Scholar 

  7. Hequet O et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864–71.

    Article  CAS  PubMed  Google Scholar 

  8. Lotrionte M et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112(12):1980–4.

    Article  CAS  PubMed  Google Scholar 

  9. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869–79.

    Article  CAS  PubMed  Google Scholar 

  10. Nabhan C et al. Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012;156(2):196–204.

    Article  PubMed  Google Scholar 

  11. van Dalen, E.C., et al., Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev, 2010(3): p. Cd005006.

  12. van Dalen, E.C., et al., Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, 2011(6): p. Cd003917.

  13. Fumoleau P et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results. Ann Oncol. 2006;17(1):85–92.

    Article  CAS  PubMed  Google Scholar 

  14. Ryberg M et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058–67.

    Article  CAS  PubMed  Google Scholar 

  15. Yancy CW et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.

    Article  PubMed  Google Scholar 

  16. Seicean S et al. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420–6. This study showed that beta-blockers were cardioprotective in breast cancer patients receiving trastuzumab and anthracycline-based chemotherapy.

    Article  CAS  PubMed  Google Scholar 

  17. Todorova VK et al. Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model. PLoS ONE. 2012;7(11):e48398.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Hensley ML et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127–45.

    Article  CAS  PubMed  Google Scholar 

  19. Russell SD et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416–21.

    Article  CAS  PubMed  Google Scholar 

  20. Spano J-P et al. Current targeted therapies in breast cancer: clinical applications in the elderly woman. Oncologist. 2011;16(8):1144–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Du XL et al. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol. 2011;28 Suppl 1:S80–90.

    Article  PubMed  Google Scholar 

  22. Chen J et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12.

    Article  CAS  PubMed  Google Scholar 

  23. Tarantini L et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol. 2012;23(12):3058–63. This study showed that female breast cancer patients over the age of 60 had a higher incidence of trastuzumab-based cardiotoxicity compared to younger women.

    Article  CAS  PubMed  Google Scholar 

  24. Chavez-MacGregor M et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222–8.

    Article  CAS  PubMed  Google Scholar 

  25. Serrano C et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012;23(4):897–902. This study showed that elderly breast cancer patients with cardiovascular risk factors and over the age of 70 had a high incidence of trastuzumab-related cardiotoxicity.

    Article  CAS  PubMed  Google Scholar 

  26. Adamo V et al. The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology. 2014;86(1):16–21.

    Article  CAS  PubMed  Google Scholar 

  27. Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19. This study showed that there were no increased cardiotoxic effects when pertuzumab was added to trastuzumab and docetaxel chemotherapy in HER2-positive metastatic breast cancer patients.

    Article  CAS  PubMed  Google Scholar 

  28. Genentech, I., Herceptin (trastuzumab) prescribing information. 2014.

  29. Schutz FA et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 2012;30(8):871–7. This meta-analysis of 10 randomized controlled trials showed that there was an increased risk of fatal adverse events in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors.

    Article  CAS  PubMed  Google Scholar 

  30. Procopio G et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer. 2013;108(2):311–8. This meta-analysis showed that age does not impact drug-related adverse events in renal cell cancer patients treated with sorafenib.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Tsai HT et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol. 2013;24(6):1574–9.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Scappaticci FA et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9.

    Article  PubMed  Google Scholar 

  33. Advani RH et al. Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leuk Lymphoma. 2012;53(4):718–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Choueiri TK et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29(6):632–8.

    Article  CAS  PubMed  Google Scholar 

  35. Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis. 2013;16(2):289–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Atallah E et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–7.

    Article  CAS  PubMed  Google Scholar 

  37. Marcolino MS et al. The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients. Hematol Oncol. 2011;29(3):124–30.

    Article  CAS  PubMed  Google Scholar 

  38. Estabragh ZR et al. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res. 2011;35(1):49–51.

    Article  CAS  PubMed  Google Scholar 

  39. Greil R et al. Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe. Onkologie. 2011;34(5):233–8.

    Article  CAS  PubMed  Google Scholar 

  40. Polk A et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974–84. This study systematically reviewed the manifestations of symptomatic cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine.

    Article  CAS  PubMed  Google Scholar 

  41. Kosmas C et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82.

    Article  CAS  PubMed  Google Scholar 

  42. Jensen SA et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol. 2010;28(36):5280–6.

    Article  CAS  PubMed  Google Scholar 

  43. Brockstein BE et al. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant. 2000;25(8):885–94.

    Article  CAS  PubMed  Google Scholar 

  44. Squibb, B.-M., Cytoxan (cyclophosphamide) package insert. 2005.

  45. Haugnes HS et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649–57.

    Article  PubMed  Google Scholar 

  46. Traish AM et al. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl. 2009;30(1):10–22.

    Article  CAS  PubMed  Google Scholar 

  47. Keating NL et al. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol. 2013;64(1):159–66.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Hill BT et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol. 2011;152(5):561–9.

    Article  PubMed  Google Scholar 

  49. Stillwell EE et al. Retrospective outcome data for hematopoietic stem cell transplantation in patients with concurrent coronary artery disease. Biol Blood Marrow Trans. 2011;17(8):1182–6. This study showed that in cancer patients with or without pre-existing coronary artery disease, there was no significant difference in the treatment-related mortality, mortality at 1 year, and length of stay during hematopoietic stem cell transplantation.

    Article  Google Scholar 

  50. Steuter JA et al. Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT). Bone Marrow Transplant. 2013;48(7):963–5.

    Article  CAS  PubMed  Google Scholar 

  51. Spina M et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17(6):838–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Richard Steingart, Dipti Gupta, Frank Evans, and Nandini Yadav have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Dipti Gupta, Nandini Yadav, Frank Evans & Richard M. Steingart

  2. Weill Cornell Medical College, New York, NY, USA

    Dipti Gupta & Richard M. Steingart

Authors
  1. Dipti Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nandini Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard M. Steingart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dipti Gupta.

Additional information

This article is part of the Topical Collection on Elderly and Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, D., Yadav, N., Evans, F. et al. Chemotherapy-Induced Cardiomyopathy in the Elderly. Curr Cardiovasc Risk Rep 8, 414 (2014). https://doi.org/10.1007/s12170-014-0414-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-014-0414-5

Keywords

Search

Navigation